TG Therapeutics (NASDAQ:TGTX) PT Raised to $49.00

TG Therapeutics (NASDAQ:TGTX) had its price target boosted by HC Wainwright from $45.00 to $49.00 in a report released on Thursday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on the stock. JPMorgan Chase & Co. reissued an overweight rating and set a $25.00 price target on shares of TG Therapeutics in a research note on Thursday, April 18th. StockNews.com cut TG Therapeutics from a buy rating to a hold rating in a research note on Saturday, February 24th. The Goldman Sachs Group boosted their target price on TG Therapeutics from $12.00 to $13.00 and gave the company a neutral rating in a research note on Thursday, February 29th. B. Riley lifted their price target on TG Therapeutics from $24.00 to $29.00 and gave the stock a buy rating in a research note on Monday, February 5th. Finally, LADENBURG THALM/SH SH increased their price objective on TG Therapeutics from $39.00 to $40.00 and gave the company a buy rating in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $29.83.

TG Therapeutics Price Performance

TGTX stock opened at $16.19 on Thursday. TG Therapeutics has a one year low of $6.46 and a one year high of $35.67. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18. The stock has a market cap of $2.50 billion, a PE ratio of 70.39 and a beta of 2.33. The firm has a 50 day simple moving average of $15.25 and a two-hundred day simple moving average of $14.46.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $63.47 million for the quarter, compared to the consensus estimate of $54.60 million. TG Therapeutics had a return on equity of 33.79% and a net margin of 14.24%. The company’s revenue for the quarter was up 713.5% on a year-over-year basis. During the same period last year, the firm earned ($0.28) EPS. On average, analysts predict that TG Therapeutics will post -0.11 EPS for the current fiscal year.

Insider Transactions at TG Therapeutics

In related news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the sale, the director now owns 215,229 shares of the company’s stock, valued at $3,437,207.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors have recently bought and sold shares of TGTX. New York State Common Retirement Fund grew its holdings in shares of TG Therapeutics by 1.2% during the 4th quarter. New York State Common Retirement Fund now owns 56,208 shares of the biopharmaceutical company’s stock worth $960,000 after acquiring an additional 663 shares during the period. Kestra Advisory Services LLC grew its stake in TG Therapeutics by 8.2% in the third quarter. Kestra Advisory Services LLC now owns 16,342 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 1,240 shares during the period. Principal Financial Group Inc. raised its holdings in TG Therapeutics by 3.9% in the first quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company’s stock worth $538,000 after purchasing an additional 1,322 shares in the last quarter. Arizona State Retirement System lifted its position in TG Therapeutics by 3.5% during the third quarter. Arizona State Retirement System now owns 40,411 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 1,356 shares during the period. Finally, Valeo Financial Advisors LLC boosted its holdings in shares of TG Therapeutics by 2.4% during the 4th quarter. Valeo Financial Advisors LLC now owns 63,300 shares of the biopharmaceutical company’s stock valued at $1,081,000 after buying an additional 1,500 shares in the last quarter. 58.58% of the stock is owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.